---
title: "Moderna publishes Science Day 2026 presentation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290839905.md"
description: "Moderna released its Science Day 2026 presentation, detailing its mRNA platform and highlighting three near-term value drivers: infectious disease vaccines, personalized cancer vaccine intismeran autogene, and rare disease therapeutics. Key upcoming catalysts include U.S. flu vaccine approval, norovirus Phase 3 data, adjuvant melanoma data, and PA registrational study results. The company also emphasized mRED, an AI-driven engine for Horizon 2 and 3 programs, to accelerate clinical proof-of-concept for new modalities."
datetime: "2026-06-25T13:26:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290839905.md)
  - [en](https://longbridge.com/en/news/290839905.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290839905.md)
---

# Moderna publishes Science Day 2026 presentation

-   Moderna published its Science Day 2026 medical research presentation outlining its mRNA platform, built on chemistry, sequence engineering, targeting elements. \* Slides highlight three established modalities as near-term value drivers: infectious disease vaccines, personalized cancer vaccine intismeran autogene, rare disease therapeutics. \* Key upcoming catalysts flagged include U.S. flu vaccine approval, norovirus Phase 3 data, event-driven Phase 3 adjuvant melanoma data, PA registrational study data. \* Presentation also details mRED as the engine for Horizon 2 and 3 programs, using AI to speed decisions and move new modalities to clinical proof-of-concept. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief on June 25, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [MRNX.US](https://longbridge.com/en/quote/MRNX.US.md)
- [MRNY.US](https://longbridge.com/en/quote/MRNY.US.md)

## Related News & Research

- [This Stock Has Already Doubled This Year and Is Still Racing Towards a Major Catalyst](https://longbridge.com/en/news/290916339.md)
- [Moderna advances in vivo CAR-T candidate mRNA-6007 into early development for autoimmune diseases](https://longbridge.com/en/news/290822266.md)
- [Moderna spotlights expanding mRNA pipeline at Science Day event](https://longbridge.com/en/news/290819631.md)
- [Moderna Maintained at Hold as Analyst Weighs Leading mRNA Platform Against Early-Stage Pipeline Risks](https://longbridge.com/en/news/290970667.md)
- [Moderna’s mRNA flu vaccine passes FDA AdCom, review underway](https://longbridge.com/en/news/290435765.md)